Does the media prefer KYMR or MLYS?

In the previous week, Kymera Therapeutics had 10 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 14 mentions for Kymera Therapeutics and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.23 beat Kymera Therapeutics' score of 0.59 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MLYS or PTGX?

In the previous week, Protagonist Therapeutics had 9 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 13 mentions for Protagonist Therapeutics and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.23 beat Protagonist Therapeutics' score of 1.09 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, MLYS or SYRE?

Spyre Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mineralys Therapeutics N/A N/A -$154.65M -$2.05 N/A Spyre Therapeutics N/A N/A -$155.20M -$1.95 N/A

Is MLYS or SYRE more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mineralys Therapeutics N/A -27.92% -26.98% Spyre Therapeutics N/A -39.07% -26.23%

Does the media favor MLYS or SYRE?

In the previous week, Spyre Therapeutics had 17 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 21 mentions for Spyre Therapeutics and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.23 beat Spyre Therapeutics' score of 0.86 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 9 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MLYS or QGEN?

In the previous week, Qiagen had 8 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 12 mentions for Qiagen and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.23 beat Qiagen's score of 1.01 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MLYS or TGTX?

In the previous week, TG Therapeutics had 30 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 34 mentions for TG Therapeutics and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.23 beat TG Therapeutics' score of 0.08 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Mineralys Therapeutics (MLYS) Competitors

$26.90 +0.05 (+0.17%)

As of 02:13 PM Eastern

Compare

MLYS vs. KYMR, PTGX, SYRE, QGEN, and TGTX

Should you buy Mineralys Therapeutics stock or one of its competitors? MarketBeat compares Mineralys Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mineralys Therapeutics include Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Spyre Therapeutics (SYRE), Qiagen (QGEN), and TG Therapeutics (TGTX).

How does Mineralys Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Kymera Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

84.5% of Mineralys Therapeutics shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mineralys Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Kymera Therapeutics currently has a consensus price target of $124.96, indicating a potential upside of 19.09%. Mineralys Therapeutics has a consensus price target of $49.33, indicating a potential upside of 82.58%. Given Mineralys Therapeutics' higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Mineralys Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$51.48M	167.67	-$311.35M	-$3.57	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

In the previous week, Kymera Therapeutics had 10 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 14 mentions for Kymera Therapeutics and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.23 beat Kymera Therapeutics' score of 0.59 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mineralys Therapeutics beats Kymera Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Protagonist Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Mineralys Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market.

In the previous week, Protagonist Therapeutics had 9 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 13 mentions for Protagonist Therapeutics and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.23 beat Protagonist Therapeutics' score of 1.09 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Mineralys Therapeutics has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Protagonist Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Protagonist Therapeutics	$74.06M	125.84	-$130.15M	-$1.81	N/A

Mineralys Therapeutics presently has a consensus price target of $49.33, suggesting a potential upside of 82.58%. Protagonist Therapeutics has a consensus price target of $123.14, suggesting a potential downside of 15.03%. Given Mineralys Therapeutics' higher possible upside, equities research analysts clearly believe Mineralys Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Summary

Protagonist Therapeutics beats Mineralys Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Spyre Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Mineralys Therapeutics presently has a consensus price target of $49.33, suggesting a potential upside of 82.58%. Spyre Therapeutics has a consensus price target of $110.15, suggesting a potential upside of 6.30%. Given Mineralys Therapeutics' higher probable upside, research analysts plainly believe Mineralys Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Mineralys Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.03, suggesting that its stock price is 203% more volatile than the broader market.

In the previous week, Spyre Therapeutics had 17 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 21 mentions for Spyre Therapeutics and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.23 beat Spyre Therapeutics' score of 0.86 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	9 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Spyre Therapeutics	N/A	N/A	-$155.20M	-$1.95	N/A

84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Mineralys Therapeutics' return on equity of -27.92% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Spyre Therapeutics	N/A	-39.07%	-26.23%

Summary

Mineralys Therapeutics and Spyre Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Qiagen?

Mineralys Therapeutics (NASDAQ:MLYS) and Qiagen (NYSE:QGEN) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

In the previous week, Qiagen had 8 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 12 mentions for Qiagen and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.23 beat Qiagen's score of 1.01 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Qiagen	$2.10B	4.09	$424.88M	$1.91	21.83

Mineralys Therapeutics presently has a consensus target price of $49.33, suggesting a potential upside of 82.58%. Qiagen has a consensus target price of $43.34, suggesting a potential upside of 3.97%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Mineralys Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Qiagen has a net margin of 19.16% compared to Mineralys Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Qiagen	19.16%	14.40%	8.40%

Mineralys Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

Summary

Qiagen beats Mineralys Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Mineralys Therapeutics compare to TG Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

In the previous week, TG Therapeutics had 30 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 34 mentions for TG Therapeutics and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.23 beat TG Therapeutics' score of 0.08 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Mineralys Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

Mineralys Therapeutics presently has a consensus price target of $49.33, suggesting a potential upside of 82.58%. TG Therapeutics has a consensus price target of $58.67, suggesting a potential upside of 17.56%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

TG Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
TG Therapeutics	$616.29M	12.40	$447.18M	$2.74	18.21

TG Therapeutics has a net margin of 55.22% compared to Mineralys Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 73.23% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
TG Therapeutics	55.22%	73.23%	37.22%

84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

TG Therapeutics beats Mineralys Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Mineralys Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLYS vs. The Competition

Export

Metric	Mineralys Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.23B	$11.74B	$6.90B	$12.84B
Dividend Yield	N/A	2.73%	2.60%	9.78%
P/E Ratio	-13.19	791.47	281.40	25.46
Price / Sales	N/A	745.68	571.76	79.70
Price / Cash	N/A	72.42	71.79	50.79
Price / Book	3.31	10.78	12.85	6.07
Net Income	-$154.65M	$2.82B	$3.49B	$348.34M
7 Day Performance	3.17%	2.78%	2.38%	3.09%
1 Month Performance	-7.21%	-1.47%	-2.91%	-3.00%
1 Year Performance	100.74%	195.74%	75.57%	20.91%

Mineralys Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLYS Mineralys Therapeutics	3.6009 of 5 stars	$26.90 +0.2%	$49.33 +83.4%	+100.2%	$2.22B	N/A	N/A	28	Upcoming Earnings
KYMR Kymera Therapeutics	2.147 of 5 stars	$106.10 -3.6%	$124.68 +17.5%	+145.5%	$8.72B	$51.48M	N/A	170	News Coverage Earnings Report Analyst Forecast
PTGX Protagonist Therapeutics	1.5329 of 5 stars	$135.22 -0.3%	$123.00 -9.0%	+154.8%	$8.68B	$46.02M	N/A	120	News Coverage Positive News Earnings Report Analyst Forecast Gap Up
SYRE Spyre Therapeutics	2.5332 of 5 stars	$98.75 -1.3%	$101.42 +2.7%	+518.6%	$8.68B	N/A	N/A	73	Trending News Earnings Report Analyst Forecast Insider Trade
QGEN Qiagen	3.8933 of 5 stars	$41.89 +2.0%	$43.34 +3.5%	-20.2%	$8.62B	$2.10B	21.84	5,654	News Coverage Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLYS) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. KYMR, PTGX, SYRE, QGEN, and TGTX

How does Mineralys Therapeutics compare to Kymera Therapeutics?

Summary

How does Mineralys Therapeutics compare to Protagonist Therapeutics?

Summary

How does Mineralys Therapeutics compare to Spyre Therapeutics?

Summary

How does Mineralys Therapeutics compare to Qiagen?

Summary

How does Mineralys Therapeutics compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. KYMR, PTGX, SYRE, QGEN, and TGTX

How does Mineralys Therapeutics compare to Kymera Therapeutics?

Which has more risk and volatility, KYMR or MLYS?

Do institutionals & insiders believe in KYMR or MLYS?

Is KYMR or MLYS more profitable?

Do analysts recommend KYMR or MLYS?

Which has higher earnings & valuation, KYMR or MLYS?

Does the media prefer KYMR or MLYS?

Summary

How does Mineralys Therapeutics compare to Protagonist Therapeutics?

Which has more risk & volatility, MLYS or PTGX?

Does the media favor MLYS or PTGX?

Is MLYS or PTGX more profitable?

Do institutionals and insiders have more ownership in MLYS or PTGX?

Which has stronger earnings & valuation, MLYS or PTGX?

Do analysts prefer MLYS or PTGX?

Summary

How does Mineralys Therapeutics compare to Spyre Therapeutics?

Do analysts prefer MLYS or SYRE?

Which has more volatility and risk, MLYS or SYRE?

Does the media favor MLYS or SYRE?

Which has higher earnings and valuation, MLYS or SYRE?

Do insiders & institutionals have more ownership in MLYS or SYRE?

Is MLYS or SYRE more profitable?

Summary

How does Mineralys Therapeutics compare to Qiagen?

Does the media favor MLYS or QGEN?

Which has higher valuation and earnings, MLYS or QGEN?

Do analysts rate MLYS or QGEN?

Do insiders & institutionals have more ownership in MLYS or QGEN?

Is MLYS or QGEN more profitable?

Which has more risk and volatility, MLYS or QGEN?

Summary

How does Mineralys Therapeutics compare to TG Therapeutics?

Does the media favor MLYS or TGTX?

Which has more volatility and risk, MLYS or TGTX?

Do analysts recommend MLYS or TGTX?

Which has preferable earnings and valuation, MLYS or TGTX?

Is MLYS or TGTX more profitable?

Do insiders and institutionals have more ownership in MLYS or TGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools